Abstract 987P
Background
We aimed to evaluate the safety and efficacy of lenvatinib in Korean population under real-world practice.
Methods
Patients were prospectively entered at 29 clinical sites through an observational post-marketing study in Korea, funded by Eisai. Patients were treated with lenvatinib according to the approved indication of uHCC. For safety analysis, Adverse Drug Reactions (ADRs) were collected. ADR was defined as AEs where the causal relationship with lenvatinib was not 'unlikely'. The efficacy was assessed by investigators as completed response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). Objective response rate (ORR) was defined as CR or PR in the efficacy analysis set. Statistical analysis was conducted to identify which demographic and clinical factors were related to ORR.
Results
658 patients were included in the safety analysis set. The mean daily dose was 7.8mg/day and 10.1mg/day in patients with a body weight of < 60kg and ≥ 60kg. The relative dose intensity related to tolerance was 97% and 84%, respectively. ADRs > grade 3 were reported in 1% (8/658). The most common ADRs > grade 3 were ‘palmar-plantar erythrodysaesthesia syndrome’ (0.3%, 2/658). In the efficacy analysis set, 513 patients were included. The results were as follows: CR, 1% (5/513); PR, 13% (66/513); SD, 45% (231/513); and PD, 41% (211/513). Among the demographic and clinical factors, ORR was significantly different depending on the total treatment duration (p <0.001).
Table: 987P
Objective response rate n (%) | No. of Subjects n (%) | p-value | |
Total treatment duration | |||
< 3 months | 12 (6) | 191 (38) | <0.001 |
3 months ∼ < 6 months | 21 (13) | 165 (32) | |
6 months ∼ < 9 months | 15 (19) | 78 (15) | |
9 months or above | 23 (30) | 76 (15) | |
Total | 71 (14) | 510 (100) |
Conclusions
Lenvatinib in Korean patients with uHCC was generally well tolerated. The efficacy of treatment varied significantly with regards to the total treatment duration. Patients with longer treatment duration showed higher ORR.
Clinical trial identification
E7080-M082-509
Editorial acknowledgement
We acknowledge the significant contribution of Prof. Kang in reviewing abstract.
Legal entity responsible for the study
Eisai Korea and the authors.
Funding
Eisai.
Disclosure
J.J. Kim: Other, Institutional, Project Lead: Eisai Korea. All other authors have declared no conflicts of interest.
Resources from the same session
1009P - Network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma: A comparison of objective response rates
Presenter: Gagandeep Kaur
Session: Poster session 18
1010P - A parametric network meta-analysis of first-line systemic therapies for advanced hepatocellular carcinoma related to overall survival
Presenter: Akanksha Sharma
Session: Poster session 18
1011P - A prospective study of TACE combined with lenvatinib plus sintilimab for HCC with portal vein tumor thrombus
Presenter: Xiaoyan Ding
Session: Poster session 18
1012P - First-in-human study of ABSK-011, a novel, highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor for treating advanced hepatocellular carcinoma (HCC) with FGF19 overexpression
Presenter: Ann-Lii Cheng
Session: Poster session 18
1013TiP - Refinement and validation of a comprehensive clinical diagnostic model (GAMAD) for early detection of hepatocellular carcinoma: A multicenter, prospective study protocol
Presenter: Tian Yang
Session: Poster session 18
1014TiP - Efficacy and safety of recombinant human adenovirus type 5 injection combined with transhepatic arterial embolization sequential thermal ablation for medium-and high-risk recurrent liver cancer: a prospective, open-label, randomized controlled study
Presenter: Jianjun Li
Session: Poster session 18
1015TiP - A Prospective, phase II clinical study of tislelizumab monotherapy or in combination with lenvatinib for neoadjuvant treatment of resectable hepatocellular carcinoma
Presenter: Tianqiang Song
Session: Poster session 18